$IMNM Cashflow Statement | Understand Stock

$IMNM

$18.77 +$0.88 (4.92%) Close

$IMNM Overview Financial Statements SEC Filings Executives News Red Flags Capital Raising Ownership Insider Transactions Congressional Trades

Financial Statements

Income Statement Balance Sheet Cashflow Statement

Consolidated Statements of Cash Flows

In millions of USD; shares in millions, except per-share amounts

	FY2025 12 months to Dec 31, 2025	FY2024 12 months to Dec 31, 2024	FY2023 12 months to Dec 31, 2023	FY2022 12 months to Dec 31, 2022	FY2021 12 months to Dec 31, 2021
Cash flows from operating activities:
Net loss
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization
Amortization of right-of-use asset
Accretion of discounts on marketable securities
Share-based compensation expense
Deferred rent
Forgiveness of PPP Loan
Loss on disposal of property and equipment
Charge for purchase of in-process research and development assets, including upon achievement of milestones
Changes in operating assets and liabilities:
Prepaid expenses and other assets
Accounts payable
Accrued expenses and other current liabilities
Deferred revenue
Other long-term liabilities
Operating lease liabilities
Net cash used in operating activities

Cash flows from investing activities:
Maturities of marketable securities
Purchases of marketable securities
Purchases of property and equipment
Purchases of in-process research and development assets
Cash acquired in connection with Morphimmune merger, net of transaction costs
Net cash provided by (used in) investing activities
Cash flows from financing activities:
Proceeds from public offerings
Proceeds from issuance of common stock under ATM
Proceeds from sale of common stock and common stock warrants
Payment of issuance costs related to the sale of common stock and common stock warrants
Payment of Series A convertible preferred stock issuance costs
Payment of equipment loan payable
Payment of offering costs
Proceeds from PIPE transaction
Proceeds from exercise of stock options
Proceeds from exercise of common stock warrants
Net cash provided by financing activities

Net increase in cash and cash equivalents and restricted cash
Cash and cash equivalents and restricted cash at beginning of period
Cash and cash equivalents and restricted cash at end of period
Cash paid for interest
Operating lease right-of-use asset and lease liability recorded upon adoption of ASC 842
Offering costs included in accounts payable
Supplemental disclosures of non-cash investing and financing activities:
Issuance of common stock and stock-based equity awards for the Morphimmune merger
Purchases of in-process research and development assets, including payments owed upon achievement of development milestones, in accounts payable and accrued expenses
Purchases of property and equipment in accounts payable and accrued expenses and other current liabilities
Remeasurement of operating right-of-use asset and lease liability due to lease modifications
Offering costs in accounts payable and accrued expenses and other current liabilities
Issuance of common stock in exchange for in-process research and development assets
Purchase of in-process research and development assets in accounts payable and accrued expenses
Net liabilities assumed from purchases of in-process research and development assets
Right-of-use assets obtained in exchange for operating lease liabilities
Issuance of common stock to certain board of directors in lieu of accrued compensation
Reconciliation of cash and cash equivalents and restricted cash:
Cash and cash equivalents
Restricted cash

Comments